Phonphimon Wongthida, Ph.D.
Affiliations: | 2010 | Virology and Gene Therapy | College of Medicine - Mayo Clinic |
Area:
Virology Biology, Molecular BiologyGoogle:
"Phonphimon Wongthida"Parents
Sign in to add mentor| Richard G. Vile | grad student | 2010 | College of Medicine - Mayo Clinic | |
| (Understanding, and exploiting, the contribution of the immune system to the therapeutic efficacy of oncolytic virotherapy with vesicular stomatitis virus (VSV).) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Kottke T, Tonne J, Evgin L, et al. (2021) Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy. Nature Communications. 12: 1930 |
| Huff AL, Evgin L, Thompson J, et al. (2020) Vesicular Stomatitis Virus Encoding a Destabilized Tumor Antigen Improves Activation of Anti-tumor T Cell Responses. Molecular Therapy : the Journal of the American Society of Gene Therapy |
| Evgin L, Huff AL, Wongthida P, et al. (2020) Oncolytic virus-derived type I interferon restricts CAR T cell therapy. Nature Communications. 11: 3187 |
| Wongthida P, Schuelke MR, Driscoll CB, et al. (2020) Ad-CD40L mobilizes CD4 T cells for the treatment of brainstem tumors. Neuro-Oncology |
| Driscoll CB, Schuelke MR, Kottke T, et al. (2020) APOBEC3B-mediated corruption of the tumor cell immunopeptidome induces heteroclitic neoepitopes for cancer immunotherapy. Nature Communications. 11: 790 |
| Schuelke MR, Wongthida P, Thompson J, et al. (2019) Diverse immunotherapies can effectively treat syngeneic brainstem tumors in the absence of overt toxicity. Journal For Immunotherapy of Cancer. 7: 188 |
| Evgin L, Huff AL, Kottke T, et al. (2019) Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from Frontline Treatment. Cancer Immunology Research |
| Vile R, Evgin L, Kottke T, et al. (2019) Abstract B138: Cancer immunotherapy with APOBEC3B-induced heteroclitic library tumor cell vaccines and immune checkpoint blockade Cancer Immunology Research. 7 |
| Huff AL, Wongthida P, Kottke T, et al. (2019) Abstract A133: APOBEC3 confers resistance to oncolytic VSV therapy Cancer Immunology Research. 7 |
| Evgin L, Huff AL, Wongthida P, et al. (2019) Abstract A029: Unexpected antagonism between oncolytic virus derived type I interferon and EGFRvIII CAR T-cells Cancer Immunology Research. 7 |